In a phase 1b trial, tarlatamab plus an anti-PD-L1 in first-line maintenance achieves a median survival of more than 2 years in extensive-stage small cell lung cancer.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/record-survival-seen-tarlatamab-maintenance-sclc-2025a1000oe8?src=rss
Author :
Publish date : 2025-09-16 07:06:00
Copyright for syndicated content belongs to the linked Source.
